Diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine - Biologic Drug Details

Summary for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Recent Clinical Trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine clinical trials

Pharmacology for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Bordetella Pertussis Vaccine Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine Inactivated Poliovirus Vaccine
Chemical Structure	Diphtheria Toxoid Pertussis Vaccine Poliovirus Vaccines Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Derived from Patent Text Search

No patents found based on company disclosures

Diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory of Diphtheria, Tetanus, and Acellular Pertussis (DTaP) Vaccines

Introduction

The Diphtheria, Tetanus, and Acellular Pertussis (DTaP) vaccine is a crucial component in global immunization programs, protecting against three infectious diseases: diphtheria, tetanus, and pertussis. This article delves into the market dynamics and financial trajectory of DTaP vaccines, highlighting key trends, challenges, and opportunities.

Market Size and Growth

The global DTaP vaccine market is projected to grow significantly, with a compound annual growth rate (CAGR) of 8.20% from 2024 to 2032, reaching $11.02 billion by 2032[1]. In 2023, the market size was valued at $5.61 billion, indicating a substantial increase in demand for these vaccines[1].

Market Drivers

Several factors contribute to the growth of the DTaP vaccine market:

• Increased Demand for Combination Vaccines: The rise in demand for tetravalent and pentavalent combination vaccines has significantly contributed to the market's growth. This shift is driven by initiatives like those from the Global Alliance for Vaccines and Immunizations (GAVI)[1][4].
• Government and Non-Government Initiatives: Government and non-governmental organizations' efforts to promote vaccination drives have positively impacted the market size. These initiatives have led to increased awareness and higher vaccination rates[1][4].
• Technological Advancements: The development of new technologies has improved vaccine manufacturing processes, leading to more efficient production and better therapeutic applications[1].

Regional Market Analysis

The market is predominantly driven by regional dynamics:

• North America: Occupies the largest market share due to high vaccination rates and increased awareness about the importance of DTaP vaccines[1][4].
• Europe: The second-largest market, with a significant share in the global DTaP vaccine market[1].
• Asia Pacific: Expected to witness the highest growth rate due to the adoption of new technologies and rising demand for DTP vaccines[1][4].

Product Segmentation

The DTaP vaccine market is segmented based on product types:

• DTaP Vaccines: These vaccines use acellular pertussis components, which are less effective but cause fewer side effects compared to whole-cell vaccines. They hold the maximum market share due to their widespread adoption in high-income countries[3][4].
• DTwP Vaccines: Whole-cell pertussis vaccines are more effective but have higher side effect profiles. They are less commonly used in high-income countries but remain crucial in regions with limited access to advanced vaccines[3].

Challenges

Despite the growth, several challenges affect the market:

• High Development Costs: The initial capital investments needed to develop and manufacture vaccines can range from $700 million to over $1 billion, making it a significant financial burden[5].
• Adverse Events: Adverse events associated with vaccination can hamper market growth and public confidence in vaccines[1].
• Inadequate Access: Limited access to vaccines in underdeveloped countries restricts market growth and hampers global health initiatives[4].

Opportunities

Emerging markets offer lucrative opportunities for key players in the DTaP vaccine market:

• Rise in Healthcare Expenditure: Increasing healthcare expenditure in emerging markets drives demand for advanced vaccines like DTaP[4].
• Innovative Technologies: The development of new technologies and innovative vaccine designs can enhance market growth by improving vaccine efficacy and reducing side effects[1][5].

Key Players

Major players in the DTaP vaccine market include:

• GlaxoSmithKline plc (GSK): Holds a significant market share globally, along with other major pharmaceutical companies like Sanofi[4].

Conclusion

The DTaP vaccine market is poised for significant growth driven by increased demand for combination vaccines, government initiatives, and technological advancements. However, challenges such as high development costs and adverse events need to be addressed to ensure sustained market growth.

Key Takeaways

1. Market Size: The global DTaP vaccine market is projected to reach $11.02 billion by 2032.
2. Growth Drivers: Increased demand for combination vaccines, government initiatives, and technological advancements.
3. Regional Dynamics: North America dominates the market, followed by Europe and Asia Pacific.
4. Product Segmentation: DTaP vaccines hold the maximum market share due to their widespread adoption.
5. Challenges: High development costs, adverse events, and inadequate access to vaccines in underdeveloped countries.
6. Opportunities: Emerging markets offer lucrative opportunities driven by increasing healthcare expenditure and innovative technologies.

FAQs

1. What is the current market size of the DTaP vaccine?

   • The current market size of the DTaP vaccine was valued at $5.61 billion in 2023[1].

2. What are the primary drivers of the DTaP vaccine market growth?

   • The primary drivers include increased demand for combination vaccines, government initiatives, and technological advancements[1][4].

3. Which region dominates the DTaP vaccine market?

   • North America dominates the DTaP vaccine market due to high vaccination rates and increased awareness[1][4].

4. What are the challenges faced by the DTaP vaccine market?

   • The challenges include high development costs, adverse events, and inadequate access to vaccines in underdeveloped countries[1][4].

5. Who are the key players in the DTaP vaccine market?

   • Major players include GlaxoSmithKline plc (GSK) and Sanofi[4].